Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
11/2003
11/06/2003WO2003009855A3 Organo-phosphorous compounds for activating gamma/delta t cells
11/06/2003WO2003008564A3 Methods of polyvalent bacteriophage preparation for the treatment of bacterial infections
11/06/2003WO2003007686A3 Use of copper chelators to inhibit the inactivation of protein c
11/06/2003WO2002094313A3 Vaccine composition
11/06/2003WO2002085934A3 Antibacterial peptides, compositions containing same and uses thereof
11/06/2003WO2002083711A3 Molecular mimetics of meningococcal b epitopes which elicit functionally active antibodies
11/06/2003WO2002081741A3 Use of products of genes of the 2'-5' oligoadenylate synthetase family (oas) for screening antiviral agents and for detecting responsiveness to flaviviridae infection
11/06/2003WO2002076979A8 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists
11/06/2003WO2002072631A3 Mhc molecule constructs and their usesfor diagnosis and therapy
11/06/2003WO2002072600A3 Monoclonal antibodies to the clfa protein and method of use in treating or preventing infections
11/06/2003WO2002066037A3 Antiviral method of use
11/06/2003WO2002061105A3 Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (ptpc)
11/06/2003WO2002061070A8 Environmentally regulated genes, involved in the virulence of streptococcus suis
11/06/2003WO2002060949A8 Glycoforms a fas ligand inhibitory protein analog
11/06/2003WO2002026785A3 Epitopes of virus hepatitis c specifically cd4+ t lymphocytes
11/06/2003WO2002024891A9 B7-like molecules and uses thereof
11/06/2003WO2002018369A8 Peptidomimetic protease inhibitors
11/06/2003WO2001080633A8 Surfactant protein d for the prevention and diagnosis of pulmonary emphysema
11/06/2003US20030208783 Transcriptional activator fusion proteins which comprises both tetracycline controlled transactivator proteins and reverse tetracycline transactivator proteins
11/06/2003US20030208082 Nitrogen compounds such as 4,5-diisopropyl-1-methyl-2-styryl -1H-imidazole, used as glutamate receptor antagonists, for prophylaxis of psychological disorders, as anxiolytic agents and analgesics
11/06/2003US20030208079 Heterocyclic amines such as (2S,3S)-3-((1R)-6-methoxy-1-methyl -1-trifluoromethylisochroman-7-yl)methylamino-2-phenyl piperidine, used as analgesics, antiinflammatory agents, or for proph7ylaxis of cardiovascular disorders
11/06/2003US20030208069 Method for producing 8-methoxy-quinoline carboxylic acids
11/06/2003US20030208067 Inhibitors of protein kinase for the treatment of disease
11/06/2003US20030208059 Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
11/06/2003US20030208058 B7-like polypeptides and polynucleotides
11/06/2003US20030208046 Pseudo native chemical ligation
11/06/2003US20030208035 Antifungal and/or antibacterial peptides, preparation methods, compositions containing same and methods of treating mammals and/or plants
11/06/2003US20030207943 Administering dopamine, serotonin, and norepinephrine reuptake inhibitor (sibutramine) for treatment of neuropsychiatric disorders
11/06/2003US20030207939 Novel 3-substituted urea derivatives and medicinal use thereof
11/06/2003US20030207937 Such as ethyl-2,2-4,4-tetramethyl-chroman-6-carboxylate; for retinoid-treatable conditions
11/06/2003US20030207919 For treating, preventing, reducing inflammation, pain, fever,gastrointestinal disorders; decreasing gastrointestinal, renal and other toxicities resulting from use of nonsteroidal antiinflammatory drugs; multiplicity of compounds
11/06/2003US20030207899 Heterocyclylaminomethyloxazo-lidinones as antibacterials
11/06/2003US20030207895 Tissue factor antagonists and methods of use thereof
11/06/2003US20030207881 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission
11/06/2003US20030207880 Heterocycle carboxamides as antiviral agents
11/06/2003US20030207877 Pyridoquinoxaline antivirals
11/06/2003US20030207871 Sulphonamide derivatives as prodrugs of aspartyl protease inhibitors
11/06/2003US20030207870 Aryl ureas with angiogenisis inhibiting activity
11/06/2003US20030207864 Novel arylsulfonanilide derivatives and their use as pharmacologically active agents. The compositions find particular use as pharmacological agents in the treatment of disease states, particularly cancer, psoriasis, vascular
11/06/2003US20030207861 Novel compounds as NS3-serine protease inhibitors of hepatitis C virus
11/06/2003US20030207859 Novel substituted succinic acid metallo-beta-lactamase inhibitors and their use in treating bacterial infections
11/06/2003US20030207852 Treating female sexual dysfunction are provided. A pharmaceutical composition formulated so as to contain a selected vasoactive agent is administered to the vagina, vulvar area or urethra of the individual undergoing treatment.
11/06/2003US20030207850 Hormone replacement therapy
11/06/2003US20030207846 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
11/06/2003US20030207843 Treating viral infections caused by retroviruses. In a particular aspect of the invention, there are provided methods for treating viral infections caused by retroviruses which have developed resistance to antivirals, such as, for
11/06/2003US20030207841 Novel nucleoside and oligonucleotide analogues
11/06/2003US20030207836 Ovo nucleotide immuno-stimulant. The VAF contains one or more DNA constructs, each having a DNA molecule and a vector. Each of the DNA molecule contains one or more genes or gene fragments, each encoding an antigenic peptide of an avian
11/06/2003US20030207834 The present invention relates to methods and compositions containing oligonucleotides suitable for administration to humans and other mammals.
11/06/2003US20030207798 Hair growth promoting agent including a cyclosporin derivative as an active ingredient, and more particularly, a hair growth promoting agent including a cyclosporin A derivative substituted in the 3-position as an active ingredient.
11/06/2003US20030207797 Glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful
11/06/2003US20030207772 Warming and nonirritating lubricant compositions and method of comparing irritation
11/06/2003US20030207450 Derived from the neuroretina of the eye ex vivo and in vivo
11/06/2003US20030207435 Have increased anti-coagulation activity and resistance to inactivation by serpins
11/06/2003US20030207403 For diagnosis or treatment of diseases with beta 10 polypeptides and alpha 2/ beta 10 heterodimers or their respective binding agents, such as thyroid gland disorders
11/06/2003US20030207318 Kinesin-like motor protein
11/06/2003US20030207262 Compounds, methods of screening, and in vitro and in vivo uses involving anti-apoptotic genes and anti-apoptotic gene products
11/06/2003US20030206974 Antiviral substances from plant cuticular and epicuticular material
11/06/2003US20030206971 Aqueous acidulant part comprising an activator acid, a rheology modifier or a pseudoplastic thickener, a chlorine dioxide stable visual indicator system; alkali metal chlorite
11/06/2003US20030206967 Sodium metasilicate, borax,sodium thiosulfate, potassium carbonate, refined cane sugar and water; improvement in disease resistance, weight gain rate, crop yield, crop quality, and harvest time
11/06/2003US20030206956 Topical treatment of prevention of ocular infections
11/06/2003US20030206941 Fast dissolving orally consumable films
11/06/2003US20030206938 Also bactericidal or bacteriostatic contact lens coated with the peptide
11/06/2003US20030206930 Soft gelatin capsule manufacture
11/06/2003US20030206929 Vegetable oil phase containing dispersed Amphotercin B; water phase containing dissolved glycerin, mannitol, or dextrose tonicity modifiers; emulsifier such as natural phosphatides
11/06/2003US20030206924 Equine herpesvirus vaccine
11/06/2003US20030206923 Combination of soybean, mushroom and mung bean provides phytoestrogens, beta-glucans, saponins, inositol hexaphosphate, and lectins.
11/06/2003US20030206917 Transferring a protein to a cell by coating the cell surface with a lipidated protein; and contacting said cell with a fusion protein having affinity for said lipidated protein and capable of binding to a cell surface receptor
11/06/2003US20030206900 Vectors derived from antibodies for transferring substances into cells
11/06/2003US20030206898 Use of anti-TNFalpha antibodies and another drug
11/06/2003US20030206885 Vaccine immunotherapy for immune suppressed patients
11/06/2003US20030206869 Delivery of antidepressants through an inhalation route
11/06/2003US20030206868 Immune response modifier compounds for treatment of th2 mediated and related diseases
11/06/2003US20030205229 Drug delivery apparatus
11/06/2003CA2827114A1 Multi plasmid system for the production of influenza virus
11/06/2003CA2484067A1 Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors
11/06/2003CA2483819A1 Non-immunosuppressive imunogenic or vaccine composition comprising a mutated e7 protein of the hpv-16 virus
11/06/2003CA2483636A1 3,4-dihydroquinolin-2(1h)-one compounds as nr2b receptor antagonists
11/06/2003CA2483564A1 Chimeric camp factors for vaccination against streptococcus infection
11/06/2003CA2483504A1 4,4-(disubstituted)piperidine derivatives with ccr3 antagonism
11/06/2003CA2483500A1 Pyrimidine-2, 4, 6-trione metallo-proteinase inhibitors
11/06/2003CA2483441A1 Mannose binding lectin and uses thereof
11/06/2003CA2483314A1 Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
11/06/2003CA2483281A1 11-deoxy azalide antibacterials
11/06/2003CA2483253A1 Use of compounds having ccr antagonism
11/06/2003CA2483221A1 9-oxime macrolide antibacterials
11/06/2003CA2483220A1 Oxolide antibacterials
11/06/2003CA2483155A1 Benzothiadiazepine derivatives, processes for their preparation and pharmaceutical compositions containing them
11/06/2003CA2483091A1 3-substituted amino-1h-indole-2-carboxylic acid and 3-substituted amino-benzo' b! thiophene-2-carboxylic acid derivatives as interieukin-4 gene expression inhibitors
11/06/2003CA2483075A1 Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors
11/06/2003CA2482946A1 Multi plasmid system for the production of influenza virus
11/06/2003CA2482019A1 Use of conjugated linoleic acid or derivative thereof in the treatment of influenza
11/06/2003CA2481449A1 Method and compositions for identifying anti-hiv therapeutic compounds
11/06/2003CA2481285A1 Non nucleoside reverse transcriptase inhibitors
11/06/2003CA2480497A1 Substituted pyrazine derivatives
11/06/2003CA2480092A1 N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
11/06/2003CA2479943A1 Method for reduction of residual organic solvent in carbomer
11/05/2003EP1359156A2 Papilloma virus vaccine
11/05/2003EP1359153A1 Beta-lactamase inhibiting compounds
11/05/2003EP1359147A1 4,4-disubstituted-1,4-dihydro-2H-3,1-benzoxazin-2-ones useful as HIV reverse transcriptase inhibitors and processes for making the same
11/05/2003EP1358884A1 Preventives for microbial infections
1 ... 1129 1130 1131 1132 1133 1134 1135 1136 1137 1138 1139 1140 1141 1142 1143 1144 1145 1146 1147 1148 1149 ... 1798